(C) World Health Organization
This story was originally published by World Health Organization and is unaltered.
. . . . . . . . . .



Utilizing data on antimicrobial use and knowledge to inform regulatory changes to antibiotic packaging and support antimicrobial stewardship efforts in Bangladesh [1]

[]

Date: 2024-09

Background

Antimicrobial stewardship efforts undertaken to date include the development of national treatment guidelines and the piloting of selected interventions in a small number of hospitals. The Directorate General of Drug Administration (DGDA), operating under the Ministry of Health & Family Welfare, serves as the national regulatory authority tasked with ensuring the quality, safety, and efficacy of pharmaceutical products through the enforcement of relevant legislation. Enforcing the regulations to prohibit over-the-counter sale of prescription-only medicines, including antibiotics, has been challenging due to the 86 local manufacturers producing 98% of medicines for the pharmaceutical market and the vast number of pharmacies in the country (approximately 202,500 in 2022), leading to a large proportion of antibiotics being obtained over the counter and self-medication with antibiotics. Compounding this issue is a lack of understanding about antibiotics and AMR among the general population. This lack of awareness further perpetuates inappropriate antibiotic usage in Bangladesh.

To address these challenges effectively, concerted efforts are needed to strengthen regulatory enforcement, enhance public awareness campaigns, and promote antimicrobial stewardship practices across all sectors of society. Collaboration between governmental bodies, healthcare professionals, pharmaceutical manufacturers, and community stakeholders is crucial in mitigating the threat of AMR and safeguarding the effectiveness of antimicrobial treatments in Bangladesh.

In addition, significant increases observed in the use of antibiotics in Bangladesh prompted investigation and intervention. Total antibiotic use more than doubled from 19.8 defined daily doses per 1,000 inhabitants per day (DID) in 2018 to 55.5 DID in 2021 and 48.9 DID in 2022 (compared with the median of 16.6 DID in 26 countries contributing data to the Global Antimicrobial Resistance and Use Surveillance System [GLASS] in 2020). In 2022, Access group antibiotics made up 29% of overall national use, falling well below the 60% target and indicating widespread overuse and misuse of broad-spectrum Watch antibiotics. Major increases of three- to four-fold were seen in the use of third- generation cephalosporins (e.g., ceftriaxone), sulfamethoxazole/trimethoprim, fluoroquinolones (e.g., moxifloxacin) and nitroimidazoles (e.g., metronidazole). Third- generation cephalosporins, largely cefixime and ceftriaxone, made up 33.3% of total national antibiotic use. This is concerning given their use is associated with an increased risk of infection and colonization with extended-spectrum beta-lactamases (ESBLs). With technical support from the World Health Organization (WHO) Country Office in Bangladesh and Staten’s Serum Institute in Denmark, alongside financial backing from the Fleming Fund, the DGDA investigated the escalating antibiotic use in the country. This collaborative effort aimed to identify the underlying causes and devise interventions to tackle the issue effectively. Subsequently, an initiative was launched to overhaul antibiotic packaging for all antibiotics manufactured and sold within Bangladesh. This initiative was a proactive measure to address inappropriate antibiotic use and combat AMR in the country.

Antibiotic packaging initiative

A baseline survey was conducted in November and December 2021 by Assistant Director of DGDA, Ms. S.M. Sabrina Yesmin, which has provided valuable insights into the knowledge levels of pharmacy retailers regarding antibiotics and AMR in Bangladesh. The survey encompassed 427 pharmacy retailers across 8 divisions of the country and utilized a mixed-method approach to gather data. Approximately one-third of retailers were not suitably qualified as pharmacists and over two-thirds could not readily identify examples of antibiotics. To complement the survey, key informant interviews were conducted between December 2021 and January 2022 with a range of policymakers, healthcare professionals, manufacturers, pharmacy retailers, graduate pharmacists, development partners, and researchers. Interviewees were asked a series of questions about the adequacy of existing labeling of antibiotics and to provide feedback on different proposed designs of antibiotic packaging and the feasibility of their implementation. The consensus among stakeholders was that existing primary packaging (which comes into direct contact with the antibiotic e.g. blister pack for tablets) and secondary packaging (outer packaging to protect storage and transportation e.g. cardboard box) of antibiotics did not distinguish it from other medicines, making it difficult for both retailers and consumers to distinguish antibiotics from other medicines.

The results of the survey and interviews, as well as proposed changes to antibiotic packaging, were presented by DGDA to the Bangladesh Association of Pharmaceutical Industries for discussion in January 2022. The association initially raised concerns that regulations could limit market access for existing antibiotics, reducing profitability and disincentivizing manufacturers from producing antibiotics. They also highlighted that adhering to new regulations would necessitate significant investment in updating packaging processes and ensuring compliance, leading to increased operational costs. However, evidence generated from the survey and meetings held to sensitize manufacturers on the impact of AMR helped to alleviate these concerns.

[END]
---
[1] Url: https://www.who.int/news/item/25-09-2024-utilizing-data-on-antimicrobial-use-and-knowledge-to-inform-regulatory-changes-to-antibiotic-packaging-and-support-antimicrobial-stewardship-efforts-in-bangladesh

Published and (C) by World Health Organization
Content appears here under this condition or license: Creative Commons CC-BY-NC-SA 3.0 IGO.

via Magical.Fish Gopher News Feeds:
gopher://magical.fish/1/feeds/news/who/

You are viewing proxied material from magical.fish. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.